- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00105352
Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials
OBJECTIVE:
This study is being conducted by the Type 1 Diabetes TrialNet Study Group, funded by the National Institutes of Health, in collaboration with the European C-Peptide Group. The goal is to evaluate comparability and reproducibility of measures of beta cell function in type 1 diabetes comparing the mixed meal tolerance tests (MMTT) and glucagon stimulation test (GST). These two tests will be compared to assess the relationship between the MMTT and IV (intravenous) Glucagon stimulated C-peptide responses as measured by time to peak C-peptide and AUC (area under the curve) values.
Based on the understanding that type 1 diabetes results from an immune mediated loss of pancreatic beta cells, therapeutic trials and newer measures of beta cell function can be evaluated as endpoints for clinical trials. Direct assessment of residual beta cell function is an appropriate endpoint, as retention of beta cell function in patients with T1D is known to result in improved glycemic control and reduced hypoglycemia, retinopathy and nephropathy. Endogenous beta cell function or insulin secretion is best measured by determination of C-peptide (which is co-secreted with insulin in a 1:1 molar ratio). Intervention studies over the past few decades have usually used measurement of C-peptide. However, the relationship between these or other measures of beta cell function has not been well studied. The relative advantages of one measure over another in terms of variability, sensitivity and burden to the subject is unknown. In addition, the optimal conditions for the conduct of the test need to be determined.
An important goal is to develop an international consensus about the conduct of metabolic tests in the context of large, multicenter trials involving type 1 diabetes (T1D) by balancing the scientific data with the burden on the subject.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Overview:
The study is a multi-center, two-arm, randomized clinical trial. Each participant will undergo four tests within a limited period according to the test sequence assignment. The tests will randomly start with either MMTT or GST.
Specific Aims
- To compare the reliability of the MMTT and Glucagon stimulated C-peptide responses as measured by time to peak C-peptide on MMTT, and the peak and AUC values on both tests.
- To determine the relationship between MMTT and Glucagon stimulated C-peptide responses as measured by time to peak C-peptide on MMTT and peak and AUC values on both tests.
- To determine the impact of basal glucose, peak glucose, age of participant, time from diagnosis, and basal C-peptide with respect to the reliability of measures and relationship between MMTT and Glucagon results.
- Describe the palatability of, patient compliance with, and adverse effects of each test (MMTT vs. GST) and to compare the participant and investigator burden to conduct the MMTT and Glucagon tests.
TEST INFORMATION:
- Mixed Meal Tolerance Test (MMTT):
BOOST is a liquid meal (like a milkshake) containing a standard amount of fat, protein, and carbohydrate. BOOST raises blood sugar and causes the pancreas to produce insulin. After drinking BOOST, about one-half teaspoon of blood will be drawn through an IV line in the arm after 15, 30, 60, 90, and 120 minutes. (Using an IV line avoids multiple needle sticks). The test takes about 2 hours.
- Glucagon Stimulation Test (GST):
Glucagon is a hormone that circulates in the blood and stimulates insulin secretion. Glucagon will be injected into the bloodstream through an IV line, and about one-half teaspoon of blood will be drawn five times during ten minutes. The test takes about 30 minutes.
OTHER TEST INFORMATION:
- Participants will have tests on four different days over a six week period. Participants will have either a) two MMTTs and then two GSTs OR b) two GSTs and then two MMTTs. Each test will be done 3-10 days apart.
- Participants will follow a special high carbohydrate diet (150 grams) for at least three days prior to each study visit. Dietary information will be provided.
- Participants will fast overnight (at least 8 hours) and arrive at the clinic between 7 AM - 10 AM.
- It is essential that participants have a blood glucose level of 70-200 mg/dl in the morning before starting the test. If blood glucose is too high or too low the morning of the test, the test will be re-scheduled on another day.
- Tests will be re-scheduled if, on the morning of the test, your blood sugar or ketones are not within acceptable ranges. Testing could take up to eight visits if tests need to be re-scheduled.
- Participants will learn whether their pancreas is still secreting insulin and, if so, how much insulin is being secreted. This information may help their diabetes health care team design for them a better insulin regimen and diabetes management program to improve their longterm blood sugar control.
- This study will help researchers learn which test (MMTT or GST) is best to use in other research studies looking at treatments that may stop or delay type 1 diabetes.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Victoria
-
Parkville, Victoria, Australia, 3050
- Walter and Eliza Hall Institute of Medical Research
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G-1X8
- University of Toronto
-
-
-
-
-
Turku, Finland, FIN-20520
- University of Turku
-
-
-
-
-
Milan, Italy, +39-02-2643 2818
- Vita-Salute San Raffaele University
-
-
-
-
-
Bristol, United Kingdom, BS10 5NB UK
- University of Bristol
-
-
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
San Francisco, California, United States, 94143-0434
- University of California San Francisco
-
Stanford, California, United States, 94305-5208
- Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80262
- Barbara Davis Center for Childhood Diabetes, University of Colorado
-
-
Florida
-
Gainesville,, Florida, United States, 32610
- University of Florida
-
Miami, Florida, United States, 33101
- University of Miami School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children, Indiana University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Joslin Diabetes Center/ Children's Hospital Boston
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 58944
- University of Minnesota
-
-
New York
-
New York, New York, United States, 10032
- Naomi Berrie Diabetes Center, Columbia University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh of UPMC
-
-
Texas
-
Dallas, Texas, United States, 75390-8858
- University of Texas Medical Center at Dallas
-
-
Washington
-
Seattle, Washington, United States, 358285
- Benaroya Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Informed consent obtained from participants (over 12 years of age) and parents (for participants below 18 years of age). Assent is obtained from younger children.
- Age 8 - 35 years at the time of inclusion
- Body weight > 30 kg
- Type 1 diabetes defined by: ADA (American Diabetes Association) criteria or judgment of physician
- Duration of diabetes: 1 month to 3* years (*The TrialNet Coordinating Center will monitor fasting C-peptide levels as they are reported to ensure that a wide range of values is included. This review may result in widening the duration of diabetes window to allow for subjects with low C-peptide).
- Must maintain good glycemic control
- Be willing to travel to a TrialNet Clinical Center for a minimum of four separate visits that are spaced 3-10 days apart, and be willing to complete the study within a six week period.
Exclusion Criteria:
- Actual treatment with drugs influencing beta cell function (e.g. oral hypoglycaemic agents, beta-2-receptor agonists)
- Actual treatment with drugs influencing insulin sensitivity (e.g. steroids)
- Significant concomitant disease likely to interfere with glucose metabolism (e.g. febrile illness within the prior 3 days)
- Expected poor compliance
- If a female of child-bearing age, currently pregnant or not using a form of birth control
- Any other condition that by the judgement of the investigator may be potentially harmful to the patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Stimulated C-peptide response derived from the 2-hour MMTT and the glucagon stimulation test (GST)
|
Time to peak C-peptide on MMTT, and the peak and AUC values from each test
|
Co-efficient of reproducibility of the MMTT, and the GST, provided from the duplicate tests within the same individuals
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Jay S Skyler, M.D., University of Miami
Publications and helpful links
General Publications
- Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 2004 Jan;53(1):250-64. doi: 10.2337/diabetes.53.1.250. Erratum In: Diabetes. 2004 Jul;53(7):1934.
- Greenbaum CJ, Harrison LC; Immunology of Diabetes Society. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes. 2003 May;52(5):1059-65. doi: 10.2337/diabetes.52.5.1059. No abstract available. Erratum In: Diabetes. 2003 Oct;52(10):2643.
- Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 2008 Oct;31(10):1966-71. doi: 10.2337/dc07-2451. Epub 2008 Jul 15.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MMTTGST (IND) (completed)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Mixed Meal Tolerance Test
-
Medical College of WisconsinJuvenile Diabetes Research Foundation; Benaroya Research InstituteCompleted
-
Nanjing Medical UniversityNot yet recruitingNutrition | Metabolism DisorderChina
-
University of AarhusDanish Diabetes AcademyCompletedType 2 Diabetes | NAFLDDenmark
-
Pediatric Clinical Research PlatformUniversity Hospital, Geneva; University of Geneva, SwitzerlandRecruitingGenetic Predisposition to Disease | Type 1 Diabetes MellitusSwitzerland
-
Medical University InnsbruckUnknownCardiovascular Diseases | Diabetes Mellitus | Familial Renal GlucosuriaAustria
-
RTI InternationalBoston University; National Cancer Institute (NCI); Eunice Kennedy Shriver National... and other collaboratorsRecruitingDietary Habits | Nutrition | HealthUnited States
-
National Institute of Diabetes and Digestive and...Not yet recruitingObesity | Healthy VolunteerUnited States
-
Stephanie B. Seminara, MDRecruitingPregnancy | Healthy Volunteers | Insulin | Glucose | WomenUnited States
-
University of PennsylvaniaActive, not recruiting
-
Liverpool Heart and Chest Hospital NHS Foundation...WithdrawnCystic FibrosisUnited Kingdom